About Us

Mission Statement

We aim to develop medical foods as alternatives to treat pain and other severe illnesses normally treated with pharmaceutical drugs derived from opioids. Our mission is to improve patient health, provide practitioners with diversified therapeutic treatment options, and introduce alternative solutions to people using synthetic drugs with harmful side effects, all at a reduced cost. 

Company Overview

Health Advance Inc. is a Wyoming corporation trading on OTC Markets under ticker symbol HADV. The company operates within the U.S.A and Asia-Pacific as a researcher and developer of biotechnology primarily focused on creating medical food supplements for medicine alternatives to treat pain and other severe illnesses usually treated with pharmaceutical drugs derived from opioids.  Our strategy is to attract opportunities in the health care industry through the development of patented product formulations for medical foods Cebidofen and Polyoxyfen, and Gynspeq, a food additive made from botanical extract blends that include Kava and Mitrigyna Speciosa. Furthermore, the Company will explore ways to use the product formulations through research studies and clinical trials with medical schools, research organizations, hospitals, and governmental agencies. 

Corporate Management

Greg Shusterman - President & Chairman 

Shusterman was appointed as Director and Vice Chairman at Health Advance in 2017, and was the Acting Chairman and Executive Director through January 2018. Before joining Health Advance he served as a consultant to national surgical clinics MiVIP Surgery Centers and oBand Inc. Additionally, Shusterman was co-founder and Executive Vice President at Gubagoo Inc., a leading customer communications solution serving thousands of clients including Ford, Fiat, Chrysler, BMW, Volkswagon, Kia and Land Rover. His entrepreneurial experience has helped bring start up companies through growth and expansion phases to maturity and exit.

Christian Diesveld - Director & Vice President of Investor Relations

Diesveld is a Canadian citizen and UK resident who has worked previously in various senior leadership positions for a number of companies, including, but not limited to, Hantian Labs Limited, a pending acquisition of the Company, where Mr. Diesveld was recently named UK CEO of the Year – Small Enterprise in the Health and Wellness sector.  Additionally, Diesveld brings over twenty years experience in capital markets, specializing in private equity and venture capital with FCA licensed firms.  Diesveld attended York University where he majored in International Business and continued to work at BMO Nesbitt Burns as an Investment Advisor.

Dr. Muhammad Mukhtar, Ph.D. - Special Advisor to President & Chairman

Dr. Muhammad Mukhtar Ph.D. has served as a professor at the American University of Ras Al Khaimah (AURAK), United Arab Emirates. Before his arrival at AURAK, he served as Vice Chancellor/Professor of three Universities in Pakistan concomitantly – a unique honor for any academic leader. Through his wise academic leadership and innovative governance, he converted a regional higher education institution in Pakistan to one of the top-ranked in the country. Dr. Mukhtar received his Masters and MPhil in the field of Biochemistry from Pakistan and his Ph.D. in biosciences from the Drexel University of Philadelphia, USA, and also completed a Graduate Certificate in Research Management from Thomas Jefferson University in Philadelphia, USA. He served in various academic/administrative positions in the USA on an outstanding scientist (O-1) visa. Dr. Mukhtar is also an avid researcher. His laboratory developed an in-vitro model of the human blood-brain barrier to study viral neuropathogenesis. Dr. Mukhtar as Principal or Co-Investigator has received several awards from organizations including American Diabetes Association, American Society for Microbiology, Diabetes Trust Foundation, US National Institutes of Health, Pfizer Pharmaceuticals (NYSE: PFE), and the Higher Education Commission of Pakistan. Human blood-brain barrier model developed in his laboratory is extensively used to understand ferrying of viruses into the brain and finding cures for neurological ailments.

Dr. Mukhtar holds specialized Certificates in Public Health and Bioinformatics. Committed to the role of technology in biomedical research, he serves as managing editor of Frontiers in Bioscience and is on the editorial board of several research journals. He feels pride in mentoring researchers, scientists, teachers and administrators and committed professionals aspiring to excel in their practical life. He has several research publications, including peer-reviewed research, review articles, invited articles, book chapters, commissioned articles and critiques to his credit. A book describing accomplishments of Dr. Mukhtar's educational leadership has been published in Urdu language entitled "Hayat Zauq e Safar Kay Siwa Kuch Aur Naheen" and it's English Version "The Making of a Best National University" is in progress.

Dr. Christian Hong - Clinical Research Adviser, Project KLEAN

Dr. Hong currently serves as the President of New Tokyo Medical College in Micronesia and is a former AMEDD (Army Medical Department) officer, Dr. H. Christian Hong was nominated by Board of Regents on May 2012 to serve as president of New Tokyo Medical College. His nomination was confirmed by the Board of Regents the same month and he was sworn in as the first president of New Tokyo Medical College.

Prior to his New Tokyo Medical College appointment, Dr. H. Christian Hong served as Chief of Immunology, Brooke Army Medical Center (BAMC), San Antonio, Texas. Other assignments include Principal Investigator (as a Captain) at Department of Radiation Medicine, Armed Forces Radiobiology Research Institute, Uniformed Services University, Bethesda, Maryland, and Captain, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, District of Columbia.

Dr. Hong holds Diploma from U.S. Army Academy of Health Sciences; graduate and doctorate degree from New York Medical College, New York and Nova Southeastern University, Florida respectively. Additionally, he holds a professional degree in medicine. Dr. Hong was awarded Meritorious Service Medal, Joint Service Commendation Medal, Army Commendation Medal, and Army Achievement Medal.

In November 2017 Dr. Hong was appointed the Head of Project KLEAN, a cooperative founded by New Tokyo Medical College, Micro Medtech, and Health Advance in efforts to develop opioid alternatives.